BioCorRx (BICX) Stock Price

BioCorRx Price

OTC·CLOSED
0.34USD+0.00 (+0.00 %)
Market closed

Revenue at BioCorRx has contracted by 18.7% per year over the past 14 years to 7,700.00 USD. For BioCorRx, the net margin of -66,313.0% is down versus -2,891.7% a few years ago. The stock trades about 67% above its 52-week low.

BioCorRx stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of BioCorRx over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how BioCorRx stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing BioCorRx's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

BioCorRx Stock Price History
DateBioCorRx Price
7/10/20260.34 USD
7/9/20260.34 USD
7/8/20260.40 USD
7/7/20260.40 USD
7/6/20260.50 USD
7/2/20260.34 USD
7/1/20260.34 USD
6/30/20260.34 USD
6/29/20260.34 USD
6/26/20260.34 USD
6/25/20260.33 USD
6/24/20260.33 USD
6/23/20260.33 USD
6/22/20260.40 USD
6/18/20260.33 USD
6/17/20260.34 USD
6/16/20260.34 USD
6/15/20260.37 USD
6/12/20260.38 USD
6/11/20260.38 USD
6/10/20260.38 USD
6/9/20260.38 USD
6/8/20260.38 USD
6/5/20260.38 USD
6/4/20260.38 USD
6/3/20260.38 USD
6/2/20260.38 USD
6/1/20260.33 USD
5/29/20260.35 USD
5/28/20260.38 USD
5/27/20260.38 USD
5/26/20260.38 USD
5/22/20260.40 USD
5/21/20260.40 USD
5/20/20260.40 USD
5/19/20260.44 USD
5/18/20260.50 USD
5/15/20260.50 USD
5/14/20260.41 USD
5/13/20260.41 USD
5/12/20260.34 USD
5/11/20260.31 USD
5/8/20260.31 USD
5/7/20260.31 USD
5/6/20260.31 USD
5/5/20260.24 USD
5/4/20260.24 USD
5/1/20260.40 USD
4/30/20260.40 USD
4/29/20260.40 USD
4/28/20260.43 USD
4/27/20260.43 USD
4/24/20260.41 USD
4/23/20260.41 USD
4/22/20260.41 USD
4/21/20260.41 USD
4/20/20260.40 USD
4/17/20260.31 USD
4/16/20260.31 USD
4/15/20260.31 USD
4/14/20260.31 USD
4/13/20260.26 USD
4/10/20260.26 USD
4/9/20260.40 USD
4/8/20260.40 USD
4/7/20260.40 USD
4/6/20260.40 USD
4/2/20260.40 USD
4/1/20260.40 USD
3/31/20260.40 USD
3/30/20260.40 USD
3/27/20260.40 USD
3/26/20260.40 USD
3/25/20260.40 USD
3/24/20260.40 USD
3/23/20260.40 USD
3/20/20260.40 USD
3/19/20260.40 USD
3/18/20260.40 USD
3/17/20260.40 USD
3/16/20260.40 USD
3/13/20260.40 USD
3/12/20260.40 USD
3/11/20260.40 USD
3/10/20260.40 USD
3/9/20260.40 USD
3/6/20260.25 USD
3/5/20260.25 USD
3/4/20260.25 USD
3/3/20260.25 USD
3/2/20260.30 USD
2/27/20260.40 USD
2/26/20260.37 USD
2/25/20260.37 USD
2/24/20260.37 USD
2/23/20260.35 USD
2/20/20260.35 USD
2/19/20260.35 USD
2/18/20260.39 USD
2/17/20260.30 USD
2/13/20260.30 USD
2/12/20260.31 USD
2/11/20260.30 USD
2/10/20260.22 USD
2/9/20260.26 USD
2/6/20260.26 USD
2/5/20260.26 USD
2/4/20260.26 USD
2/3/20260.30 USD
2/2/20260.30 USD
1/30/20260.30 USD
1/29/20260.30 USD
1/28/20260.38 USD
1/27/20260.38 USD
1/26/20260.32 USD
1/23/20260.40 USD
1/22/20260.40 USD
1/21/20260.40 USD
1/20/20260.40 USD
1/16/20260.40 USD
1/15/20260.32 USD
1/14/20260.28 USD
1/13/20260.26 USD
1/12/20260.29 USD
1/9/20260.29 USD
1/8/20260.32 USD
1/7/20260.32 USD
1/6/20260.29 USD
1/5/20260.29 USD
1/2/20260.29 USD
12/31/20250.29 USD
12/30/20250.29 USD
12/29/20250.31 USD
12/26/20250.40 USD
12/24/20250.31 USD
12/23/20250.31 USD
12/22/20250.40 USD
12/19/20250.40 USD
12/18/20250.20 USD
12/17/20250.35 USD
12/16/20250.34 USD
12/15/20250.38 USD
12/12/20250.38 USD
12/11/20250.40 USD
12/10/20250.39 USD
12/9/20250.33 USD
12/8/20250.35 USD
12/5/20250.35 USD
12/4/20250.35 USD
12/3/20250.35 USD
12/2/20250.33 USD
12/1/20250.35 USD
11/28/20250.33 USD
11/26/20250.33 USD
11/25/20250.33 USD
11/24/20250.32 USD
11/21/20250.40 USD
11/20/20250.40 USD
11/19/20250.28 USD
11/18/20250.44 USD
11/17/20250.45 USD
11/14/20250.45 USD
11/13/20250.43 USD
11/12/20250.46 USD
11/11/20250.46 USD
11/10/20250.46 USD
11/7/20250.44 USD
11/6/20250.44 USD
11/5/20250.44 USD
11/4/20250.44 USD
11/3/20250.44 USD
10/31/20250.44 USD
10/30/20250.44 USD
10/29/20250.40 USD
10/28/20250.40 USD
10/27/20250.40 USD
10/24/20250.40 USD
10/23/20250.40 USD
10/22/20250.40 USD
10/21/20250.40 USD
10/20/20250.40 USD
10/17/20250.40 USD
10/16/20250.45 USD
10/15/20250.45 USD
10/14/20250.45 USD
10/13/20250.45 USD
10/10/20250.45 USD
10/9/20250.40 USD
10/8/20250.40 USD
10/7/20250.40 USD
10/6/20250.46 USD
10/3/20250.46 USD
10/2/20250.28 USD
10/1/20250.21 USD
9/30/20250.21 USD
9/29/20250.50 USD
9/26/20250.48 USD
9/25/20250.40 USD
9/24/20250.40 USD
9/23/20250.30 USD
9/22/20250.30 USD
9/19/20250.30 USD
9/18/20250.30 USD
9/17/20250.30 USD
9/16/20250.30 USD
9/15/20250.30 USD
9/12/20250.45 USD
9/11/20250.45 USD
9/10/20250.45 USD
9/9/20250.45 USD
9/8/20250.29 USD
9/5/20250.29 USD
9/4/20250.45 USD
9/3/20250.45 USD
9/2/20250.45 USD
8/29/20250.26 USD
8/28/20250.34 USD
8/27/20250.34 USD
8/26/20250.35 USD
8/25/20250.35 USD
8/22/20250.35 USD
8/21/20250.35 USD
8/20/20250.35 USD
8/19/20250.41 USD
8/18/20250.41 USD
8/15/20250.41 USD
8/14/20250.41 USD
8/13/20250.41 USD
8/12/20250.41 USD
8/11/20250.41 USD
8/8/20250.41 USD
8/7/20250.41 USD
8/6/20250.41 USD
8/5/20250.38 USD
8/4/20250.48 USD
8/1/20250.48 USD
7/31/20250.38 USD
7/30/20250.43 USD
7/29/20250.43 USD
7/28/20250.43 USD
7/25/20250.43 USD
7/24/20250.43 USD
7/23/20250.40 USD
7/22/20250.39 USD
7/21/20250.38 USD
7/18/20250.38 USD
7/17/20250.40 USD
7/16/20250.40 USD
7/15/20250.38 USD
7/14/20250.38 USD
Access this data via the Eulerpool API
Get Free API Key

BioCorRx Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2020
120,000.00 USD
-7.49 M USD
-3.47 M USD
Jan 1, 2021
50,000.00 USD
-5.37 M USD
-5.28 M USD
Jan 1, 2022
210,000.00 USD
-4.70 M USD
-4.37 M USD
Jan 1, 2023
89,200.00 USD
-3.74 M USD
-3.77 M USD
Jan 1, 2024
7,700.00 USD
-5.12 M USD
-5.11 M USD
Jan 1, 2025 (e)
710.23 M USD
-5.61 B USD
-2.67 M USD
Jan 1, 2026 (e)
991.29 M USD
-7.25 B USD
-2.24 M USD
Jan 1, 2027 (e)
1.30 B USD
-7.38 B USD
-1.92 M USD

BioCorRx Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jul 13, 2026, 9:36 AM
 
REVENUEB USD
REVENUE GROWTH%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
20122013201420152016201720182019202020212022202320242025e2026e2027e
–––––––––––––0.710.991.30
––––––––––––––39.5830.78
–-3.00-3.00-4.00-5.00-29.00-6.00-6.00-3.00-5.00-4.00-3.00-5.00-2.00-2.00-1.00
–––33.3325.00480.00-79.31–-50.0066.67-20.00-25.0066.67-60.00–-50.00
1.061.171.391.551.702.332.513.525.386.497.208.3410.4610.4610.4610.46
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales BioCorRx generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue BioCorRx retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare BioCorRx's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares BioCorRx has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against BioCorRx's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

BioCorRx stock margins

The BioCorRx margin analysis displays the gross margin, EBIT margin, as well as the profit margin of BioCorRx. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for BioCorRx.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
25.00 %
-6,241.67 %
-2,891.67 %
Jan 1, 2021
80.00 %
-10,740.00 %
-10,560.00 %
Jan 1, 2022
95.24 %
-2,238.10 %
-2,080.95 %
Jan 1, 2023
59.64 %
-4,192.60 %
-4,222.98 %
Jan 1, 2024
77.92 %
-66,525.98 %
-66,312.99 %
Jan 1, 2025 (e)
77.92 %
-789.43 %
-0.38 %
Jan 1, 2026 (e)
77.92 %
-731.37 %
-0.23 %
Jan 1, 2027 (e)
77.92 %
-569.59 %
-0.15 %

BioCorRx Stock Revenue, EBIT, Earnings per Share

The BioCorRx earnings per share therefore indicates how much revenue BioCorRx has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2020
0.02 USD
-1.39 USD
-0.64 USD
Jan 1, 2021
0.01 USD
-0.83 USD
-0.81 USD
Jan 1, 2022
0.03 USD
-0.65 USD
-0.61 USD
Jan 1, 2023
0.01 USD
-0.45 USD
-0.45 USD
Jan 1, 2024
0.00 USD
-0.49 USD
-0.49 USD
Jan 1, 2025 (e)
67.87 USD
-535.79 USD
-0.26 USD
Jan 1, 2026 (e)
94.73 USD
-692.82 USD
-0.21 USD
Jan 1, 2027 (e)
123.85 USD
-705.43 USD
-0.18 USD

BioCorRx business model & stock analysis

The company BioCorRx Inc is a US-American company that was founded in 2008 and is headquartered in Anaheim, California. BioCorRx specializes in the development and marketing of innovative treatment methods for alcohol and drug dependency. The history of BioCorRx began with the introduction of its flagship product, the BioCorRx Recovery Program, which is based on a novel medical technology called Naltrexone/Buprenorphine Implant. Unlike traditional methods of treating alcohol and drug addiction, which typically rely on medication and psychotherapeutic support, the BioCorRx Recovery Program is an implantable, long-term treatment system that continuously delivers the active ingredient Naltrexone or Buprenorphine into the patient's body. The idea behind this is that the active ingredients prevent withdrawal symptoms and thereby reduce the risk of relapse. In recent years, BioCorRx has expanded its product portfolio and expanded its business activities to new segments in order to further drive the company's growth. This includes, for example, the field of telemedicine services, which allow BioCorRx to offer its treatment technology and medical services through online communication. Telemedicine services such as virtual patient consultation or online group therapy programs are particularly in demand in times of COVID-19. Another focus of BioCorRx is the management of medical personnel. Studies have shown that good patient care and counseling heavily influence the success of treatment. BioCorRx has now also developed its own platform that eases and improves the management, training, and monitoring of medical staff. BioCorRx also utilizes the concept of franchise systems to market its products and services. The franchise system offers medical professionals and organizations working in the field of addiction treatment the opportunity to open their own BioCorRx clinic and offer the company's products and services in their local market. Each clinic is advised and supported by BioCorRx and must adhere to certain standards and quality criteria. In the future, BioCorRx plans to further diversify its product offering and develop new technologies to improve treatment options for alcohol and drug dependents. An example of such a technology is medication based on Ibogaine. BioCorRx has already started initial research in this direction and is actively working on pre-clinical studies. Overall, BioCorRx is a company that primarily focuses on innovative technologies for the treatment of addiction. The company has experienced substantial growth in recent years by expanding its product range and customer base, and focusing on the areas of telemedicine, personnel management, and franchise systems. With its forward-thinking technologies and strong emphasis on quality and patient satisfaction, BioCorRx is expected to continue playing an important role in addiction treatment in the years to come.

BioCorRx SWOT Analysis

Strengths

[ { "heading": "1.", "text": "Innovative" }, { "heading": "BioCorRx", "text": "Inc" } ]

[ { "heading": "2.", "text": "Strong" }, { "heading": "The", "text": "company" } ]

[ { "heading": "3.", "text": "Strategic" }, { "heading": "BioCorRx", "text": "Inc" } ]

Weaknesses

[ { "heading": "1.", "text": "Limited" }, { "heading": "Although", "text": "BioCorRx" } ]

[ { "heading": "2.", "text": "Dependence" }, { "heading": "The", "text": "company's" } ]

[ { "heading": "3.", "text": "Limited" }, { "heading": "BioCorRx", "text": "Inc" } ]

Opportunities

[ { "heading": "1.", "text": "Growing" }, { "heading": "There", "text": "is" } ]

[ { "heading": "2.", "text": "Potential" }, { "heading": "As", "text": "addiction" } ]

[ { "heading": "3.", "text": "Technological" }, { "heading": "Advancements", "text": "in" } ]

Threats

[ { "heading": "1.", "text": "Intense" }, { "heading": "The", "text": "addiction" } ]

[ { "heading": "2.", "text": "Regulatory" }, { "heading": "The", "text": "company" } ]

[ { "heading": "3.", "text": "Economic" }, { "heading": "Economic", "text": "downturns" } ]

BioCorRx Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

BioCorRx historical P/E ratio, EBIT multiple, and P/S ratio

BioCorRx annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

BioCorRx shares outstanding

The number of shares of BioCorRx was 10.46 M in 2025. This indicates how many shares BioCorRx is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2020
5.38 M Stocks
Jan 1, 2021
6.49 M Stocks
Jan 1, 2022
7.20 M Stocks
Jan 1, 2023
8.34 M Stocks
Jan 1, 2024
10.46 M Stocks
Jan 1, 2025 (e)
10.46 M Stocks
Jan 1, 2026 (e)
10.46 M Stocks
Jan 1, 2027 (e)
10.46 M Stocks

BioCorRx stock splits

In BioCorRx's history, there have been no stock splits.
Price targets and forecasts for BioCorRx are not yet available.

BioCorRx Earnings Estimates

DateEPS estimateRevenue EstimateQuarterly report
5/13/2026-0.06USD224.40 MUSD2026 Q1
3/30/2026-0.06USD204.00 MUSD2025 Q4
11/14/2025-0.06USD193.80 MUSD2025 Q3

BioCorRx shareholder structure

% Name
52.63779%
Lucido Louis Charles
Lucido Louis Charles
21.28717%
BICX Holding Company, L.L.C.
BICX Holding Company, L.L.C.
13.27560%
Galligan Joseph J
Galligan Joseph J
8.06155%
Felix (Lourdes)
Felix (Lourdes)
1.50140%
Emry (Kent)
Emry (Kent)
0.90207%
Ingargiola (Luisa)
Ingargiola (Luisa)

BioCorRx Executives and Management Board

LF

Ms. Lourdes Felix

(57)

Chief Executive Officer, Chief Financial Officer, Director · since 2012

Compensation549,846.00 USD
LL

Mr. Louis Lucido

(76)

President, Director · since 2019

Compensation85,000.00 USD
KE

Mr. Kent Emry

(57)

Independent Director · since 2013

Compensation85,000.00 USD
LI

Ms. Luisa Ingargiola

(57)

Independent Director

Compensation85,000.00 USD
JG

Mr. Joseph Galligan

(65)

Independent Director

Compensation40,680.00 USD

BioCorRx Supply Chain

BioCorRx Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
1 companies
#Name1M3M6M1Y2YTrend
1
Societal CDMO
Supplier
0.33
—
—
—
—

Frequently asked questions about BioCorRx

The business model of BioCorRx Inc revolves around providing innovative solutions for the treatment of substance abuse and addiction. The company specializes in developing and commercializing behavioral healthcare products and services. BioCorRx Inc offers the BioCorRx Recovery Program, which combines medication-assisted treatment with counseling and peer support. This comprehensive approach aims to help individuals overcome substance abuse by addressing the underlying factors contributing to addiction and promoting long-term recovery. By integrating medical and behavioral components, BioCorRx Inc strives to provide effective solutions for patients seeking to break free from addiction.

All fundamentals and in-depth analysis of BioCorRx

Our stock analysis for BioCorRx stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BioCorRx. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

BioCorRx Stock
BioCorRx Revenue→
BioCorRx Stock
BioCorRx Net Income→
BioCorRx Stock
BioCorRx P/E→
BioCorRx Stock
BioCorRx P/S→
BioCorRx Stock
BioCorRx EBIT→
BioCorRx Stock
BioCorRx Dividend→
BioCorRx Stock
BioCorRx Directors Dealings→
BioCorRx Stock
BioCorRx Stocks→
BioCorRx Stock
BioCorRx Market capitalization→
BioCorRx Stock
BioCorRx Debt→
BioCorRx Stock
BioCorRx Liabilities→
BioCorRx Stock
BioCorRx Equity→
BioCorRx Stock
BioCorRx AAQS→
BioCorRx Stock
BioCorRx Employees→
BioCorRx Stock
BioCorRx ROE→
BioCorRx Stock
BioCorRx ROA→
BioCorRx Stock
BioCorRx ROCE→
BioCorRx Stock
BioCorRx News→
BioCorRx Stock
BioCorRx Analyst Price Targets→

Health Stocks

BioCryst PharmaceuticalsBioconBiocure TechnologyBioceptBiocytogen Pharmaceuticals (Beijing) CoBioceltixBiodesixBioCardiaBiodexa PharmaceticalsBiobijou CoBioDlink International CoBioatlaAll Stocks A–Z →